NF2 is altered in 52.24% of schwannoma patients with NF2 Loss present in 1.92% of all schwannoma patients [4].

NF2 Loss is an inclusion criterion in 5 clinical trials for schwannoma, of which 2 are open and 3 are closed. Of the trials that contain NF2 Loss and schwannoma as inclusion criteria, 2 are early phase 1 (1 open) and 3 are phase 2 (1 open) [5].

NF2 is altered in 42.22% of meningioma patients with NF2 Loss present in 0.61% of all meningioma patients [4].

NF2 Loss is an inclusion criterion in 3 clinical trials for meningioma, of which 1 is open and 2 are closed. Of the trials that contain NF2 Loss and meningioma as inclusion criteria, 1 is early phase 1 (1 open) and 2 are phase 2 (0 open) [5].

NF2 is altered in 1.87% of malignant solid tumor patients with NF2 Loss present in 0.15% of all malignant solid tumor patients [4].

NF2 Loss is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain NF2 Loss and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [5].

NF2 is altered in 28.41% of malignant pleural mesothelioma patients with NF2 Loss present in 1.69% of all malignant pleural mesothelioma patients [4].

NF2 Loss is an inclusion criterion in 2 clinical trials for malignant pleural mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain NF2 Loss and malignant pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 28.41% of malignant mesothelioma patients with NF2 Loss present in 1.69% of all malignant mesothelioma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 1.28% of poorly differentiated thyroid gland carcinoma patients with NF2 Loss present in 0.69% of all poorly differentiated thyroid gland carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF2 is altered in 1.92% of sarcoma patients with NF2 Loss present in 0.67% of all sarcoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 2.56% of ovarian carcinoma patients with NF2 Loss present in 0.56% of all ovarian carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 3.51% of melanoma patients with NF2 Loss present in 0.37% of all melanoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 0.56% of anaplastic astrocytoma patients with NF2 Loss present in 0.36% of all anaplastic astrocytoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 1.58% of low grade glioma patients with NF2 Loss present in 0.3% of all low grade glioma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 1.52% of glioblastoma patients with NF2 Loss present in 0.26% of all glioblastoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 1.3% of astrocytic tumor patients with NF2 Loss present in 0.23% of all astrocytic tumor patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 1.37% of diffuse glioma patients with NF2 Loss present in 0.22% of all diffuse glioma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 1.76% of cancer patients with NF2 Loss present in 0.14% of all cancer patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and cancer as inclusion criteria, 1 is early phase 1 (0 open) [5].

NF2 is altered in 1.0% of breast carcinoma patients with NF2 Loss present in 0.07% of all breast carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 1.17% of head and neck carcinoma patients with NF2 Loss present in 0.06% of all head and neck carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 0.46% of lymphoma patients with NF2 Loss present in 0.05% of all lymphoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 1.59% of non-small cell lung carcinoma patients with NF2 Loss present in 0.02% of all non-small cell lung carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 0.35% of B-cell non-hodgkin lymphoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF2 is altered in 3.6% of bladder carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 is altered in 1.3% of colorectal carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for neurofibromatosis type 2, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and neurofibromatosis type 2 as inclusion criteria, 1 is phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 0.93% of pancreatic carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 Loss is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

NF2 is altered in 11.29% of thyroid gland undifferentiated (anaplastic) carcinoma patients [4].

NF2 Loss is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 Loss and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].